Zev A. Wainberg, MD, Highlights the Rationale for Examining Long-Term Data From Pembrolizumab/Chemo in Advanced Gastric/GEJ Adenocarcinoma

Video

Zev A. Wainberg, MD, spoke to the rationale for examining the efficacy of pembrolizumab alone and in combination with chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Gastrointestinal (GI) Cancer Symposium, Zev A. Wainberg, MD, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the GI Oncology Program at UCLA, highlighted the rationale for assessing the use of pembrolizumab (Keytruda) alone and in combination with chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma in the phase 3 KEYNOTE-062 trial (NCT02494583). Moreover, he discussed the necessity of long-term follow up data for this patient population.

Transcript:

The KEYNOTE-062 trial was launched a relatively long time ago in the world of immunotherapy in gastric cancer—about 5 years ago—in the hopes of determining the role of either pembrolizumab with chemotherapy or pembrolizumab by itself in newly diagnosed patients with gastric adenocarcinoma. Since then, there have been multiple other studies [that] have shed additional light on this topic. But this was probably the first one of [this] size to be launched to look at the role of a PD-1 inhibitor in frontline metastatic gastric cancer. The update [takes place] 2 years after the publication. Long term follow-up studies are usually done to see if there's any hint of change in efficacy or safety signals or anything like that over a 2 year period.

Reference

Wainberg ZA, Shitara K, Van Cutsem E, et al. Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. Presented at 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. January 20-22, 2022. Abstract 243.

Related Videos
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.